01 8Inomax
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 574
2019 Revenue in Millions : 571
Growth (%) : 0
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 449
2020 Revenue in Millions : 574
Growth (%) : -22
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2022 Revenue in Millions : 340
2021 Revenue in Millions : 449
Growth (%) : -24
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2023 Revenue in Millions : 303
2022 Revenue in Millions : 340
Growth (%) : -11
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2016 Revenue in Millions : 474
2015 Revenue in Millions : 185
Growth (%) : 156
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2017 Revenue in Millions : 505
2016 Revenue in Millions : 593
Growth (%) : -15
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2018 Revenue in Millions : 543
2017 Revenue in Millions : 505
Growth (%) : 8%
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2019 Revenue in Millions : 571
2018 Revenue in Millions : 543
Growth (%) : 5
LOOKING FOR A SUPPLIER?
